GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.290 +0.040 (+1.23%)

Delayed Quote Updated: 12:12 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

3 Low-Volatility Stocks with Open Questions

November 05, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

GDRX Q3 Deep Dive: Manufacturer Solutions Growth Offsets Flat Prescription Volumes

November 05, 2025

Healthcare tech company GoodRx (NASDAQ:GDRX) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per share...

Via StockStory

GoodRx’s (NASDAQ:GDRX) Q3 Sales Top Estimates

November 04, 2025

Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per...

Via StockStory

GoodRx Reports Third Quarter 2025 Results

November 04, 2025

From GoodRx Holdings, Inc.

Via Business Wire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

GoodRx Stock Buzzes As TrumpRx Drug Pricing Shake-Up Draws BofA Warning On Core Business Model ↗

October 10, 2025

Via Stocktwits

GoodRx (GDRX) Q3 Earnings Report Preview: What To Look For

November 02, 2025

Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Tuesday after market close. Here’s what to expect.

Via StockStory

Healthcare Technology Stocks Q2 Highlights: Tandem Diabetes (NASDAQ:TNDM)

October 26, 2025

Looking back on healthcare technology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Tandem Diabetes (NASDAQ:TNDM) and its peers.

Via StockStory

Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying' ↗

October 21, 2025

Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging...

Via Benzinga

Topics Government

GoodRx (GDRX): Buy, Sell, or Hold Post Q2 Earnings?

October 21, 2025

Over the past six months, GoodRx’s stock price fell to $3.94. Shareholders have lost 9.8% of their capital, which is disappointing considering the S&P 500 has climbed by 30.6%. This was partly due to...

Via StockStory

Topics Stocks Supply Chain

GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment

October 15, 2025

From GoodRx

Via Business Wire

3 Cash-Producing Stocks with Warning Signs

October 14, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗

October 09, 2025

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

Via Benzinga

Topics Government

GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

October 08, 2025

From GoodRx Holdings, Inc.

Via Business Wire

Q2 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks

October 06, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology industry, including GoodRx (NASDAQ:GDRX) and its peers.

Via StockStory

Amgen To Sell Cholesterol Drug For Approximately 60% Discount ↗

October 06, 2025

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow.

Via Stocktwits

Topics Government

GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings

October 06, 2025

From GoodRx

Via Business Wire

1 Healthcare Stock with Exciting Potential and 2 We Brush Off

October 06, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...

Via StockStory

Topics Stocks

Why GoodRx (GDRX) Stock Is Up Today

October 03, 2025

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 1.4% in the afternoon session after the stock's positive momentum continued following a potential partnership with TrumpRx and an expanded...

Via StockStory

Topics World Trade

GoodRx Launches Brand Medication Savings Program at National Retail Pharmacy

October 01, 2025

From GoodRx

Via Business Wire

Clover Health, GoodRx, Cardinal Health, McKesson, and Humana Shares Plummet, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Topics World Trade

2 of Wall Street’s Favorite Stocks Worth Investigating and 1 Facing Headwinds

September 11, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

Why GoodRx (GDRX) Shares Are Sliding Today

September 05, 2025

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) fell 4.9% in the afternoon session after a report on the U.S. job market raised concerns about a potential recession.

Via StockStory

Topics Economy Initial Public Offering Stocks

GoodRx Saddles Up With “The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing

September 02, 2025

From GoodRx

Via Business Wire

Why GoodRx (GDRX) Stock Is Up Today

August 27, 2025

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 3.1% in the morning session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

GoodRx (GDRX) Stock Is Up, What You Need To Know

August 26, 2025

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 3.7% in the afternoon session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo...

Via StockStory

Topics Artificial Intelligence Economy World Trade

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers ↗

August 25, 2025

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

Via Benzinga

Topics ETFs

Noodles, GoodRx, Micron, Custom Truck One Source, and CarMax Shares Are Falling, What You Need To Know

August 20, 2025

A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this...

Via StockStory

Topics Artificial Intelligence Economy World Trade

In today's session, these stocks are experiencing unusual volume. ↗

August 20, 2025

On Wednesday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.